Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer

Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer

Metastatic and unresectable medullary thyroid carcinoma (MTC) is often difficult to treat as it is relatively unresponsive to radiation and conventional chemotherapy. This emphasizes the importance of the development of targeted therapies for advanced MTC. Vandetanib was approved by the US Food and...

Full description

Bibliographic Details
Main Authors: Hari A. Deshpande, Khushboo Sheth, Julie A. Sosa, Sanziana A. Roman
Format: Article
Language:English
Published: SAGE Publishing 2012-01-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.4137/CMO.S8305
id doaj-2a79435bcc2f4637af390980d875b581
record_format Article
spelling doaj-2a79435bcc2f4637af390980d875b5812020-11-25T02:33:59ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492012-01-01610.4137/CMO.S8305Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid CancerHari A. Deshpande0Khushboo Sheth1Julie A. Sosa2Sanziana A. Roman3Yale University School of Medicine, New Haven, Connecticut, USA.Smt. N.H.L. Municipal Medical College, Gujarat University, India.Yale University School of Medicine, New Haven, Connecticut, USA.Yale University School of Medicine, New Haven, Connecticut, USA.Metastatic and unresectable medullary thyroid carcinoma (MTC) is often difficult to treat as it is relatively unresponsive to radiation and conventional chemotherapy. This emphasizes the importance of the development of targeted therapies for advanced MTC. Vandetanib was approved by the US Food and Drug Administration for the treatment of symptomatic or progressive MTC in patients with advanced disease in April 2011. This therapy proved to be a breakthrough in the management of MTC. We review the efficacy and safety of this novel treatment and other treatments that are being evaluated in this disease.https://doi.org/10.4137/CMO.S8305
collection DOAJ
language English
format Article
sources DOAJ
author Hari A. Deshpande
Khushboo Sheth
Julie A. Sosa
Sanziana A. Roman
spellingShingle Hari A. Deshpande
Khushboo Sheth
Julie A. Sosa
Sanziana A. Roman
Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
Clinical Medicine Insights: Oncology
author_facet Hari A. Deshpande
Khushboo Sheth
Julie A. Sosa
Sanziana A. Roman
author_sort Hari A. Deshpande
title Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
title_short Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
title_full Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
title_fullStr Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
title_full_unstemmed Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
title_sort efficacy and tolerability of pharmacotherapy options for the treatment of medullary thyroid cancer
publisher SAGE Publishing
series Clinical Medicine Insights: Oncology
issn 1179-5549
publishDate 2012-01-01
description Metastatic and unresectable medullary thyroid carcinoma (MTC) is often difficult to treat as it is relatively unresponsive to radiation and conventional chemotherapy. This emphasizes the importance of the development of targeted therapies for advanced MTC. Vandetanib was approved by the US Food and Drug Administration for the treatment of symptomatic or progressive MTC in patients with advanced disease in April 2011. This therapy proved to be a breakthrough in the management of MTC. We review the efficacy and safety of this novel treatment and other treatments that are being evaluated in this disease.
url https://doi.org/10.4137/CMO.S8305
work_keys_str_mv AT hariadeshpande efficacyandtolerabilityofpharmacotherapyoptionsforthetreatmentofmedullarythyroidcancer
AT khushboosheth efficacyandtolerabilityofpharmacotherapyoptionsforthetreatmentofmedullarythyroidcancer
AT julieasosa efficacyandtolerabilityofpharmacotherapyoptionsforthetreatmentofmedullarythyroidcancer
AT sanzianaaroman efficacyandtolerabilityofpharmacotherapyoptionsforthetreatmentofmedullarythyroidcancer
_version_ 1724811047666188288

Similar Items